Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002266:Carboxymethylcellulose Sodium / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007223:Infant; D007372:Interferons / Q000097:blood; D007938:Leukemia / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008747:Methylcellulose / Q000031:analogs & derivatives*; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage*; D011070:Poly I-C / Q000008:administration & dosage* / Q000633:toxicity; D011107:Polylysine / Q000008:administration & dosage*
D010455:Peptides; D011107:Polylysine; D008747:Methylcellulose; D007372:Interferons; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C